生物制药
单克隆抗体
蛋白质聚集
设计质量
生化工程
制造工艺
过程(计算)
药品
抗体
化学
计算机科学
计算生物学
业务
生物技术
新产品开发
药理学
医学
免疫学
生物
材料科学
生物化学
工程类
复合材料
营销
操作系统
作者
María Vázquez‐Rey,Dietmar Lang
摘要
Monoclonal antibodies have proved to be a highly successful class of therapeutic products. Large-scale manufacturing of pharmaceutical antibodies is a complex activity that requires considerable effort in both process and analytical development. If a therapeutic protein cannot be stabilized adequately, it will lose partially or totally its therapeutic properties or even cause immunogenic reactions thus potentially further endangering the patients' health. The phenomenon of protein aggregation is a common issue that compromises the quality, safety, and efficacy of antibodies and can happen at different steps of the manufacturing process, including fermentation, purification, final formulation, and storage. Aggregate levels in drug substance and final drug product are a key factor when assessing quality attributes of the molecule, since aggregation might impact biological activity of the biopharmaceutical. In this review it is analyzed how aggregates are formed during monoclonal antibody industrial production, why they have to be removed and the manufacturing process steps that are designed to either minimize or remove aggregates in the final product.
科研通智能强力驱动
Strongly Powered by AbleSci AI